Inspection Readiness
FDA to Begin Unannounced Inspections of Non-U.S. Manufacturing Facilities
Beginning August 2025, FDA inspections at non-U.S. manufacturing sites will take place without advance notice. This shift eliminates prior warning and signals a new standard for global regulatory oversight—one that demands continuous readiness.
With deep FDA expertise and regulatory professionals positioned around the world, ProPharma helps pharmaceutical, biotechnology, and medical device companies build and sustain inspection readiness—before the FDA arrives.
FDA to Begin Unannounced Inspections of Non-U.S. Manufacturing Facilities
Beginning August 2025, FDA inspections at non-U.S. manufacturing sites will take place without advance notice. This shift eliminates prior warning and signals a new standard for global regulatory oversight—one that demands continuous readiness.
With deep FDA expertise and regulatory professionals positioned around the world, ProPharma helps pharmaceutical, biotechnology, and medical device companies build and sustain inspection readiness—before the FDA arrives.
Inspection Readiness is not an option – now, more than ever, it is urgent.
Our team of experts is equipped to guide you through every step of any inspection your firm is facing, with experience and expertise. The overview below outlines how ProPharma supports clients through every stage of the inspection readiness lifecycle.
We ensure that every step towards Inspection Readiness is carefully calibrated to your needs. Our method is backed by tangible tools and training programs developed from the ground up, tailored not just to your product, but to your organization's unique scale and scope. This approach allows you to maintain focus on running your business, while we dedicate ourselves fully to your Inspection Readiness, making it our singular priority.
Inspection Readiness Experts
Unannounced inspections are coming. Preparation can't wait.
With global regulatory and quality expertise and a history of guiding clients through successful FDA inspections, ProPharma helps ensure your operations are always inspection ready—no matter when the FDA arrives.
Secure Your Regulatory Inspection Success
On average a new product takes approximately 10-15 years to develop, whether it is a biologic, a pharmaceutical product, a medical device, or a combination thereof.
- Can you risk the time and resources you invested in development by ignoring the importance of Inspection Readiness for a new product?
- Can you risk having an existing product off the market for remediation activities following a For Cause Inspection?
- Can your patients?
ProPharma's expertise covers all aspects of Inspections. Inspection Readiness Evaluation, Project Management, your Inspection Program/Process, Logistics, and Training – are just some of the most important areas of Inspection Readiness. Our expertise can become your greatest asset. We are eager to become your partner in navigating this critical process.


PAI Readiness
Pre-approval Inspections are one of the most critical inspections any Biologic, Pharmaceutical or Medical Device firm will undertake. Failure to meet FDA expectations can have a huge impact on organizations, including:
- Delays to product launch.
- Thousands, if not millions of dollars, in remediation costs.
- Lost market share.
- Loss of a firm's credibility.
PAI readiness is critical, and ProPharma is an industry leader in providing PAI Readiness to our clients.
BIMO Readiness
BIMO inspection readiness is essential for sponsors to ensure compliance with FDA regulations, protect data integrity, and uphold patient safety standards. By preparing thoroughly, sponsors:
- Ensure compliance with FDA regulations.
- Protect data integrity.
- Uphold patient safety standards.
- Help avoid costly delays.
- Prevent potential compliance issues.
- Facilitate smoother FDA inspections.

To date, we have had a 100% success rate on PAI Readiness projects for our clients
News & Insights

July 31, 2025
Pros and Cons of Working with a CRO
Explore the pros and cons of working with a Contract Research Organization (CRO) and how ProPharma sets a new standard in clinical development success.

July 28, 2025
Understanding PADER: A Key Pharmacovigilance Requirement for the U.S. Market
Learn about PADER, a crucial pharmacovigilance requirement for U.S. drug safety monitoring, and how it differs from PSUR in ensuring compliance and patient safety. Summarizing the main point of the...

July 8, 2025
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...
ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

July 29, 2025
Successfully Executing a Tech Transfer in a Week
Discover how ProPharma supported a $3B pharmaceutical tech transfer that was executed in just 3 days, relocating five complex product lines. The plan included FDA alignment, pre-approved protocols,...
.png?width=320&height=185&name=Obesity%20%E2%80%93%20Accelerated%20Timelines%20(1).png)
July 29, 2025
Obesity – Accelerated Timelines
A mid-size biotech needed fast U.S. market entry for an obesity trial. ProPharma activated 20 sites in 30 days and enrolled 300+ patients—meeting goals despite an increased sample size. Strategic...

July 29, 2025
Avoiding Common Pitfalls During FDA Inspections
Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...
.png?width=320&height=185&name=labeling-webinar-thumbnail%20(1).png)
July 22, 2025
Inside FDA Review: Crafting a Quality ANDA Labeling Submission
Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...
News & Insights